![]() The Drug Supply Chain Security Act (DSCSA) may improve transparency and inventory Increased transparency across stakeholders can help mitigate some of this. ![]() Manufacturing and quality issues are inevitable, and in a system with less redundancy the consequences can have widespread impacts. Health systems must have better visibility into areas that are vulnerable–both inside and outside of their organization–so they can anticipate and prepare for shortages. We believe that transparency will matter more in this leaner ecosystem. Now, manufacturers need to consider how resiliency can be maintained so that leaner manufacturing doesn’t require health systems and health providers to absorb additional risk and financial burden. But running leaner organizations has an unintended consequence: less redundancy and fewer back-ups.įor the drug supply chain, consolidation to reduce waste and increase profitability has also eliminated redundancy in generic drug manufacturing that historically provided a ‘cushion’ of resiliency for drug supplies. Healthcare has seen tremendous consolidation, and for decades, that pace has been accelerating. Transparency will be essential as consolidation continues Questions hospital pharmacists should ask when managing drug shortages 2. If these groups can work together on a large scale, they will set the course for a better future. It must include all stakeholders – hospitals, health care professionals, manufacturers, wholesalers, governments, consumers – to execute on a vision for a safer supply chain for American patients. The best way to improve drug supply chain management and develop better mitigation strategies is for the pharmaceutical industry to take a more collaborative approach. For example, a public benefit drug manufacturer partnered with 11 top pediatric hospitals to address shortages by making generic oncology medicines in child-size doses as well as several drugs for other life-threatening conditions. In the face of uncertainty, we’ve also seen some innovative collaborations. Joint efforts between public/private sectors such as the creation of a Strategic Active Pharmaceutical Ingredient Reserve (SAPIR) will be instrumental in defining how these products are supplied in the future. We anticipate that efforts by hospitals to have more direct control over their critical drug supply chains will continue to evolve as they work to find a sustainable, cost-effective, and safe model. 3 We expect this to be a short-term workaround. In response to this public health crisis, some US hospital groups, startups and nonprofits began making their own sterile injectables and other medicines to combat persistent drug shortages. The coronavirus pandemic put immense pressure on the hospital supply chain, including distributors for certain drugs and medical supplies like ventilators and personal protective equipment (PPE). Some innovations from managing pandemic drug shortages won’t last Here are six predictions for 2022 and beyond: 1. In our work with clients, we’ve identified several trends that may shape the future of drug shortages. 2Įxplore technology to help manage drug shortages Hospitals are looking for better ways to predict and manage drug shortages since they can negatively impact patient safety, patient care, and clinical outcomes. In some instances, hospital pharmacies must compound and modify the products, which adds significant workload and risk. ![]() Regardless of the root cause, a shortage means clinicians sometimes use costlier and less-effective medications or therapies, and hospital pharmacists may spend hours seeking alternatives. 1 Other disruptions causing drug shortages include natural disasters, manufacturing problems, and a short supply of raw materials, to name a few. While the COVID-19 pandemic caused several drug shortages and supply disruptions in the US, hospital drug shortages are nothing new.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |